Pentixapharm, a clinical-stage biopharmaceutical company, has announced a manufacturing agreement with Eckert & Ziegler Radiopharma GmbH (EZR), a subsidiary of Eckert & Ziegler SE. Under the deal, EZR will produce patient-specific doses of Y90-PentixaTher, Pentixapharm’s CXCR4-targeting radiotherapeutic, for use in clinical trials.
Eckert & Ziegler SE, a provider of isotope technology, has announced a strategic partnership with Bicycle Therapeutics, a pharmaceutical company developing Bicycle Radio Conjugates (BRC molecules). Under the agreement, Eckert & Ziegler will supply various radioisotopes and provide development and manufacturing
Eckert & Ziegler has signed a global supply agreement with GlyTherix Ltd to provide Actinium-225 (Ac-225) in support of the latter’s clinical research and development of targeted radiotherapy. This collaboration extends the companies’ existing partnership, which is focused on Lutetium-177-based
